Intra-tumor heterogeneity defines treatment-resistant HER2+ breast tumors
I. H. Rye, A. Trinh, A. Saetersdal, D. Nebdal, O. C. Lingjaerde, V. Almendro, K. Polyak, A.-L. Borresen-Dale, A. Helland, F. Markowetz, H. G. Russnes
This study examines how intra-tumor heterogeneity in HER2 expression and copy number affects treatment outcomes in HER2+ breast cancer patients.
bioRxiv · Apr 18, 2018Cancer Biology